| Autor: |
Daniel Fife, Erica A. Voss, Jill Hardin, Hany Rofael, Ira D. Solomon, Patrick B. Ryan, Paul Stang |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Neuropsychopharmacology Reports, Vol 41, Iss 3, Pp 385-392 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2574-173X |
| DOI: |
10.1002/npr2.12191 |
| Popis: |
Abstract Aim To assess label compliance in prescription of medications approved for treatment of attention‐deficit/hyperactivity disorder (ADHD) in Japan at the time of this study: methylphenidate (MPH), atomoxetine, and guanfacine. Methods Retrospective descriptive study was conducted in prevalent‐user cohorts from the Japan Medical Data Center database. Patients who were prescribed a study drug between January 1, 2013 and September 30, 2018 and were in the database for ≥30 days were included. A prescription was considered compliant if all 4 criteria were satisfied: appropriate age, daily dose not exceeding the approved maximum, no contraindicated concurrent medications, and no contraindicated conditions. Results Among 17 418 patients who were prescribed a study drug during 2013‐2018, 73% were male and 53% were children (aged 85% of patients, all prescriptions were label‐compliant for dose, and for approximately 80%, all prescriptions were label‐compliant for contraindicated conditions. We did not find evidence of widespread abuse or noncompliant use of prescribed ADHD medications. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
